Miguel F Sanmamed,Xinxin Nie,Shruti S Desai,Franz Villaroel-Espindola,Ti Badri,Dejian Zhao,Anthony W Kim,Lan Ji,Tianxiang Zhang,Edward Quinlan,Xiaoxiao Cheng,Xue Han,Matthew D Vesely,Ala F Nassar,Jingwei Sun,Yu Zhang,Tae Kon Kim,Jun Wang,Ignacio Melero,Roy S Herbst,Kurt A Schalper,Lieping Chen,Miguel F. Sanmamed,Shruti S. Desai,Anthony W. Kim,Matthew D. Vesely,Ala F. Nassar,Roy S. Herbst,Kurt A. Schalper

Abstract:Abstract Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non–small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. Significance: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker. This article is highlighted in the In This Issue feature, p. 1601

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 7 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer

Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer

Supplementary Fig. S.6 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Figure S6 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Supplementary Figure 1 from CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Figure S7 from Tumor-Derived IL33 Promotes Tissue-Resident CD8<sup>+</sup> T Cells and is Required for Checkpoint Blockade Tumor Immunotherapy

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines